GLP-1 Without Insurance: Every Cash-Pay Option Ranked (June 2026)
No insurance? You still have more GLP-1 options than ever before. Between manufacturer programs, compounded alternatives, and new oral formulations, cash-pay patients can access effective weight-loss medication starting at about $130 per month.
Here's every path, ranked by cost.
Tier 1: Compounded Semaglutide ($130–$200/mo)
Compounded semaglutide through licensed 503A pharmacies remains the most affordable GLP-1 option. These are patient-specific prescriptions compounded under state pharmacy board oversight. The medication contains the same active ingredient as Wegovy and Ozempic but is not an FDA-approved finished drug product.
Regulatory note: The FDA's proposed 503B exclusion (comments close June 29, 2026) primarily affects outsourcing facilities, not 503A pharmacies. However, the regulatory direction is toward tighter restrictions, so pricing and availability may shift.
Tier 2: Brand-Name at Manufacturer Pricing ($149–$199/mo)
Both major manufacturers now offer aggressive self-pay programs:
- Wegovy pill: $149/mo for 1.5mg and 4mg doses (through August 2026 via Novo Nordisk offer)
- Foundayo: $149/mo via LillyDirect
- Wegovy injection: $199/mo intro for first two months through NovoCare, then $349/mo
These are FDA-approved medications with no regulatory uncertainty. The tradeoff is higher cost at maintenance doses and the need for a prescriber who will route the Rx through the manufacturer's pharmacy.
Tier 3: Telehealth + Compounded ($175–$300/mo)
Mid-range telehealth platforms bundle physician consultations with compounded medication. More expensive than Tier 1 but often include more comprehensive support — dose management, nutritional guidance, messaging with your provider.
Tier 4: Brand-Name Retail ($900–$1,400/mo)
Without insurance and without manufacturer programs, brand-name GLP-1s at retail pharmacies cost $900–$1,400+ per month. This is rarely the right choice for cash-pay patients. Always check manufacturer coupons and savings programs first.